The current therapy for hepatitis C recurrence after liver transplantation OLT is based on interferon (IFN) and ribavirin (RBV) in monotherapy or combination. The rate of sustained virological response (SVR) varies between 10% and 45%. We have retrospectively analyzed factors that could predict SVR after antiviral therapy. We analyzed 42 patients who completed a cycle of therapy with natural or pegylated IFN plus RBV. There were 15 (35.7%) patients who obtained an SVR. The following factors were significantly associated with a lack of SVR: donor age >or=50 years (P = .046); donor body mass index (BMI) > 27 (P = .016); genotype 1 versus 2 to 3 (P = 0.010), aspartate transferase (AST) before therapy >or= 140 U/L (P = .046), alanine transferase before therapy >or= 280 U/L (P = .055), use of natural IFN versus pegylated IFN (P = .016). The only factors remaining after multivariate analysis were: donor BMI, AST before therapy and genotype. Our data confirmed that genotype 1 was associated with poorer outcomes; other additional parameters can influence the response to antiviral therapy.

Predictive factors of lack of response to antiviral therapy among in patients with recurrent hepatitis C after liver transplantation / Marino, M; Iemmolo, R M; Montalti, R; Bertolotti, M; Di Benedetto, F; De Ruvo, N; Cautero, N; Guerrini, G; De Blasiis, M G; Gerunda, G E. - In: TRANSPLANTATION PROCEEDINGS. - ISSN 0041-1345. - 42:4(2010), p. 1223-5. [10.1016/j.transproceed.2010.03.052]

Predictive factors of lack of response to antiviral therapy among in patients with recurrent hepatitis C after liver transplantation

Montalti, R;
2010

Abstract

The current therapy for hepatitis C recurrence after liver transplantation OLT is based on interferon (IFN) and ribavirin (RBV) in monotherapy or combination. The rate of sustained virological response (SVR) varies between 10% and 45%. We have retrospectively analyzed factors that could predict SVR after antiviral therapy. We analyzed 42 patients who completed a cycle of therapy with natural or pegylated IFN plus RBV. There were 15 (35.7%) patients who obtained an SVR. The following factors were significantly associated with a lack of SVR: donor age >or=50 years (P = .046); donor body mass index (BMI) > 27 (P = .016); genotype 1 versus 2 to 3 (P = 0.010), aspartate transferase (AST) before therapy >or= 140 U/L (P = .046), alanine transferase before therapy >or= 280 U/L (P = .055), use of natural IFN versus pegylated IFN (P = .016). The only factors remaining after multivariate analysis were: donor BMI, AST before therapy and genotype. Our data confirmed that genotype 1 was associated with poorer outcomes; other additional parameters can influence the response to antiviral therapy.
2010
Predictive factors of lack of response to antiviral therapy among in patients with recurrent hepatitis C after liver transplantation / Marino, M; Iemmolo, R M; Montalti, R; Bertolotti, M; Di Benedetto, F; De Ruvo, N; Cautero, N; Guerrini, G; De Blasiis, M G; Gerunda, G E. - In: TRANSPLANTATION PROCEEDINGS. - ISSN 0041-1345. - 42:4(2010), p. 1223-5. [10.1016/j.transproceed.2010.03.052]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/759326
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 3
social impact